公开(公告)号：WO2007111964A3

公开(公告)日：2008-06-12

申请号：PCT/US2007007178

申请日：2007-03-22

Applicant: INNOGENETICS NV ,  GOV OF THE USA AS REPRESENTED ,  DEPLA ERIK ,  PURCELL ROBERT ,  BUKH JENS ,  EMERSON SUZANNE U ,  MEUNIER JEAN-CHRISTOPHE

Inventor： DEPLA ERIK ,  PURCELL ROBERT ,  BUKH JENS ,  EMERSON SUZANNE U ,  MEUNIER JEAN-CHRISTOPHE

IPC: C07K16/00 ,  C12P21/08

CPC classification number: C07K16/109 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to anti-HCV antibodies and more specifically to neutralizing anti-HCV antibodies and their variable and complementarity determining regions (CDR). In particular, the neutralizing anti-HCV antibodies are neutralizing anti-HCV envelope protein 1 (HCV E1) antibodies. Also subject of the invention are compositions comprising these antibodies, CDRs or variable regions, and compounds comprising at least one of the CDRs or variable regions of said antibodies. Further subject of the invention are the application of any of said antibodies, CDRs, variable regions or compounds in HCV prophylaxis, therapy, and diagnosis, as well as methods for producing the antibodies.

Abstract translation: 本发明涉及抗HCV抗体，更具体地涉及中和抗HCV抗体及其可变和互补决定区（CDR）。 特别地，中和抗HCV抗体是中和的抗HCV包膜蛋白1（HCV E1）抗体。 本发明的主题还包括包含这些抗体，CDR或可变区的组合物，以及包含所述抗体的至少一个CDR或可变区的化合物。 本发明的另外的主题是HCV预防，治疗和诊断中任何所述抗体，CDR，可变区或化合物的应用以及产生抗体的方法。

公开(公告)号：WO2007111965A2

公开(公告)日：2007-10-04

申请号：PCT/US2007/007179

申请日：2007-03-22

Applicant: INNOGENETICS N.V. ,  THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  DEPLA, Erik ,  PURCELL, Robert ,  BUKH, Jens ,  EMERSON, Suzanne, U. ,  MEUNIER, Jean-Christophe

Inventor： DEPLA, Erik ,  PURCELL, Robert ,  BUKH, Jens ,  EMERSON, Suzanne, U. ,  MEUNIER, Jean-Christophe

IPC: C07K16/10

CPC classification number: C07K16/109 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to anti-HCV antibodies and more specifically to neutralizing anti-HCV antibodies and their variable and complementarity determining regions (CDR). In particular, the neutralizing anti-HCV antibodies are neutralizing anti-HCV envelope protein 1 (HCV El) antibodies. Also subject of the invention are compositions comprising these antibodies, CDRs or variable regions, and compounds comprising at least one of the CDRs or variable regions of said antibodies. Further subject of the invention are the application of any of said antibodies, CDRs, variable regions or compounds in HCV prophylaxis, therapy, and diagnosis, as well as methods for producing the antibodies.

Abstract translation: 本发明涉及抗HCV抗体，更具体地涉及中和抗HCV抗体及其可变和互补决定区（CDR）。 特别地，中和抗HCV抗体是中和的抗HCV包膜蛋白1（HCV E1）抗体。 本发明的主题还包括包含这些抗体，CDR或可变区的组合物，以及包含所述抗体的至少一个CDR或可变区的化合物。 本发明的另外的主题是HCV预防，治疗和诊断中任何所述抗体，CDR，可变区或化合物的应用以及产生抗体的方法。

公开(公告)号：WO2007111965A3

公开(公告)日：2008-07-31

申请号：PCT/US2007007179

申请日：2007-03-22

Applicant: INNOGENETICS NV ,  US GOV HEALTH & HUMAN SERV ,  DEPLA ERIK ,  PURCELL ROBERT ,  BUKH JENS ,  EMERSON SUZANNE U ,  MEUNIER JEAN-CHRISTOPHE

Inventor： DEPLA ERIK ,  PURCELL ROBERT ,  BUKH JENS ,  EMERSON SUZANNE U ,  MEUNIER JEAN-CHRISTOPHE

IPC: C07K16/00

CPC classification number: C07K16/109 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to anti-HCV antibodies and more specifically to neutralizing anti-HCV antibodies and their variable and complementarity determining regions (CDR). In particular, the neutralizing anti-HCV antibodies are neutralizing anti-HCV envelope protein 1 (HCV El) antibodies. Also subject of the invention are compositions comprising these antibodies, CDRs or variable regions, and compounds comprising at least one of the CDRs or variable regions of said antibodies. Further subject of the invention are the application of any of said antibodies, CDRs, variable regions or compounds in HCV prophylaxis, therapy, and diagnosis, as well as methods for producing the antibodies.

Abstract translation: 本发明涉及抗HCV抗体，更具体地涉及中和抗HCV抗体及其可变和互补决定区（CDR）。 特别地，中和抗HCV抗体是中和的抗HCV包膜蛋白1（HCV E1）抗体。 本发明的主题还包括包含这些抗体，CDR或可变区的组合物，以及包含所述抗体的至少一个CDR或可变区的化合物。 本发明的另外的主题是HCV预防，治疗和诊断中任何所述抗体，CDR，可变区或化合物的应用以及产生抗体的方法。

公开(公告)号：WO2007111964A2

公开(公告)日：2007-10-04

申请号：PCT/US2007/007178

申请日：2007-03-22

Applicant: INNOGENETICS N.V. ,  THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH & HUMAN SERVICES ,  DEPLA, Erik ,  PURCELL, Robert ,  BUKH, Jens ,  EMERSON, Suzanne, U. ,  MEUNIER, Jean-christophe

Inventor： DEPLA, Erik ,  PURCELL, Robert ,  BUKH, Jens ,  EMERSON, Suzanne, U. ,  MEUNIER, Jean-christophe

IPC: A61K39/42

CPC classification number: C07K16/109 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to anti-HCV antibodies and more specifically to neutralizing anti-HCV antibodies and their variable and complementarity determining regions (CDR). In particular, the neutralizing anti-HCV antibodies are neutralizing anti-HCV envelope protein 1 (HCV E1) antibodies. Also subject of the invention are compositions comprising these antibodies, CDRs or variable regions, and compounds comprising at least one of the CDRs or variable regions of said antibodies. Further subject of the invention are the application of any of said antibodies, CDRs, variable regions or compounds in HCV prophylaxis, therapy, and diagnosis, as well as methods for producing the antibodies.

Abstract translation: 本发明涉及抗HCV抗体，更具体地涉及中和抗HCV抗体及其可变和互补决定区（CDR）。 特别地，中和抗HCV抗体是中和的抗HCV包膜蛋白1（HCV E1）抗体。 本发明的主题还包括包含这些抗体，CDR或可变区的组合物，以及包含所述抗体的至少一个CDR或可变区的化合物。 本发明的另外的主题是HCV预防，治疗和诊断中任何所述抗体，CDR，可变区或化合物的应用以及产生抗体的方法。